Eli Lilly’s obesity drug helped patients lose up to 24% of their weight
Eli Lilly and Company is the pharmaceutical company’s headquarters in Alcobendas, Madrid, Spain.
Christina Arias | Cover | Getty Images
eli lillyThe experimental drug helped patients lose weight by up to 24% after almost a year. This is the largest reduction ever seen. Obesity treatment space According to new information, so far Mid-term clinical trial results Released on Monday.
The phase II trial followed 338 obese or overweight adults who received injections from pharmaceutical companies. Retatortideor weekly placebo.
Patients who received 12 milligrams of letartortide lost an average of 17.5% of their body weight, or 41 pounds, after 24 weeks, compared with 1.6% for those who received placebo.
Patients lost an average of 24.2%, or 58 pounds, after 48 weeks. The person who took the placebo lost 2.1% of her weight after the same period.
The study researchers said average weight loss did not appear to plateau past 48 weeks, suggesting that longer-term studies may show more weight loss. Eli Lilly currently Phase 3 trial.
The data suggest that Lilly’s letartortide is “the most effective anti-obesity drug ever,” said Michael Weintraub, an endocrinologist at New York University Langone Health. Twitter post.
Lilly’s other obesity drug, Munjaro, has been approved for type 2 diabetes and has been able to reduce patients’ weight by up to 21% in clinical trials.
Novo Nordisk.s Wegovy is licensed for weight loss and Up to 15% Weight Loss Seen in trials.
Like Wegovy and Mounjaro, Eli Lilly’s ritartide is a weekly injection that mimics specific hormones in the gut, altering patients’ eating habits and causing a decrease in appetite.
However, Wegovy mimics only one hunger-regulating hormone called GLP-1, whereas Mounjaro mimics GLP-1 and another hormone called GIP.
Retatortide mimics three different hunger-regulating hormones: GLP-1, GIP, and glucagon. It appears to have a more powerful effect on a person’s appetite and food satisfaction.
Summarize this content to 100 words Eli Lilly and Company is the pharmaceutical company’s headquarters in Alcobendas, Madrid, Spain.Christina Arias | Cover | Getty Imageseli lillyThe experimental drug helped patients lose weight by up to 24% after almost a year. This is the largest reduction ever seen. Obesity treatment space According to new information, so far Mid-term clinical trial results Released on Monday. The phase II trial followed 338 obese or overweight adults who received injections from pharmaceutical companies. Retatortideor weekly placebo. Patients who received 12 milligrams of letartortide lost an average of 17.5% of their body weight, or 41 pounds, after 24 weeks, compared with 1.6% for those who received placebo. Patients lost an average of 24.2%, or 58 pounds, after 48 weeks. The person who took the placebo lost 2.1% of her weight after the same period.The study researchers said average weight loss did not appear to plateau past 48 weeks, suggesting that longer-term studies may show more weight loss. Eli Lilly currently Phase 3 trial.The data suggest that Lilly’s letartortide is “the most effective anti-obesity drug ever,” said Michael Weintraub, an endocrinologist at New York University Langone Health. Twitter post. Lilly’s other obesity drug, Munjaro, has been approved for type 2 diabetes and has been able to reduce patients’ weight by up to 21% in clinical trials.Novo Nordisk.s Wegovy is licensed for weight loss and Up to 15% Weight Loss Seen in trials. Like Wegovy and Mounjaro, Eli Lilly’s ritartide is a weekly injection that mimics specific hormones in the gut, altering patients’ eating habits and causing a decrease in appetite.However, Wegovy mimics only one hunger-regulating hormone called GLP-1, whereas Mounjaro mimics GLP-1 and another hormone called GIP.Retatortide mimics three different hunger-regulating hormones: GLP-1, GIP, and glucagon. It appears to have a more powerful effect on a person’s appetite and food satisfaction.
https://www.cnbc.com/2023/06/26/eli-lilly-obesity-drug-helped-patients-lose-weight.html Eli Lilly’s obesity drug helped patients lose up to 24% of their weight